OncoMed Pharmaceuticals Expands Series B Financing with Addition of Delphi Ventures and Names Deepa Pakianathan, Ph.D., to Board of Directors
read the press release

OncoMed Pharmaceuticals Completes Series B Financing; Lead Cancer Stem Cell Product Candidate Enters Clinical Trials
read the press release

OncoMed’s first clinical trial, using an internally discovered and developed monoclonal antibody, OMP-21M18, is now open for patient enrollment. This antibody targets a pathway critical for cancer stem cells and will ultimately be tested in several common solid tumors. Details of this Phase I trial may be found at ClinicalTrials.gov.
view the study page

GlaxoSmithKline And OncoMed Pharmaceuticals Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
read the press release

OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
read more